JP2010500291A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500291A5
JP2010500291A5 JP2009523112A JP2009523112A JP2010500291A5 JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5 JP 2009523112 A JP2009523112 A JP 2009523112A JP 2009523112 A JP2009523112 A JP 2009523112A JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5
Authority
JP
Japan
Prior art keywords
antibody
csfr
csf
pharmaceutical composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009523112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500291A (ja
JP5235881B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001127 external-priority patent/WO2008017126A1/en
Publication of JP2010500291A publication Critical patent/JP2010500291A/ja
Publication of JP2010500291A5 publication Critical patent/JP2010500291A5/ja
Application granted granted Critical
Publication of JP5235881B2 publication Critical patent/JP5235881B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009523112A 2006-08-11 2007-08-10 肺疾患病態の処理 Expired - Fee Related JP5235881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904378A AU2006904378A0 (en) 2006-08-11 Treatment and prophylaxis of pulmonary disease conditions
AU2006904378 2006-08-11
PCT/AU2007/001127 WO2008017126A1 (en) 2006-08-11 2007-08-10 Treatment of pulmonary disease conditions

Publications (3)

Publication Number Publication Date
JP2010500291A JP2010500291A (ja) 2010-01-07
JP2010500291A5 true JP2010500291A5 (enExample) 2010-09-24
JP5235881B2 JP5235881B2 (ja) 2013-07-10

Family

ID=39032559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523112A Expired - Fee Related JP5235881B2 (ja) 2006-08-11 2007-08-10 肺疾患病態の処理

Country Status (10)

Country Link
US (2) US8574572B2 (enExample)
EP (2) EP2526959B1 (enExample)
JP (1) JP5235881B2 (enExample)
AU (1) AU2007283463B2 (enExample)
CA (1) CA2661446C (enExample)
DK (1) DK2056858T3 (enExample)
ES (1) ES2506065T3 (enExample)
NZ (1) NZ574285A (enExample)
PL (1) PL2056858T3 (enExample)
WO (1) WO2008017126A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2513292T3 (es) * 2009-07-31 2014-10-24 Genentech, Inc. Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
EP2477656B1 (en) 2009-09-15 2017-03-29 CSL Limited Treatment of neurological conditions
CN102869777B (zh) * 2010-04-02 2018-11-02 库尔纳公司 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
CA2986097A1 (en) * 2015-05-18 2016-11-24 The University Of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 CD11bアンタゴニストを含む劇症型急性肺炎治療用組成物
US20210179721A1 (en) * 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
BR112021010920A2 (pt) * 2018-12-04 2021-08-31 CSL Innovation Pty Ltd Método de tratamento de condições neutrofílicas
CN115768475A (zh) * 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20060093604A1 (en) 2002-08-23 2006-05-04 The Walter And Eliza Hall Institute Of Medical Research Method of treatment and prophylaxis
ES2317527T3 (es) 2005-01-13 2009-04-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Decladinosil-macrolidos que presentan actividad anti-inflamatoria.
WO2006077504A2 (en) 2005-01-18 2006-07-27 Koninklijke Philips Electronics N.V. An algorithm for growing 4-connected cores in image segmentation
CA2636990A1 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Animal model for assessing copd-related diseases

Similar Documents

Publication Publication Date Title
Ng et al. Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway
JP2005530490A5 (enExample)
JP2011500003A5 (enExample)
JP2015519891A5 (enExample)
JP2016116520A5 (enExample)
JP2013504603A5 (enExample)
JP2022501040A5 (enExample)
JP2007505627A5 (enExample)
JP2012505660A5 (enExample)
JP2009539367A5 (enExample)
JP2014511686A5 (enExample)
JP2008546390A5 (enExample)
JP2010528601A5 (enExample)
JP2012505657A5 (enExample)
JP2018510621A5 (enExample)
JP2015511625A5 (enExample)
KR20160119259A (ko) 낭포성 섬유증 및 cftr 이온 채널의 기능 결함과 관련된 기타 병태의 치료제로서 알기네이트 올리고머의 용도
CN115515560B (zh) 冠状病毒感染的治疗
JP2024516096A5 (enExample)
CN112996913A (zh) 寡聚核酸分子及其应用
WO2022026943A9 (en) Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
JP2019196384A5 (enExample)
CN108329387B (zh) 癌症相关的肿瘤特异转录本lin28b-tst及其用途
JP2023536269A5 (enExample)
JP2016533190A5 (enExample)